Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr-Jun;32(2):167-173.
doi: 10.1097/JAN.0000000000000405.

Ayahuasca: What Healthcare Providers Need to Know

Ayahuasca: What Healthcare Providers Need to Know

Deana Goldin et al. J Addict Nurs. 2021 Apr-Jun.

Abstract

Ayahuasca is a pan-Amazonian botanical hallucinogenic decoction made from a mixture of the bark of the Banisteriopsis caapi plant, containing a monoamine oxidase inhibitor, and Psychotria viridis (Rubiaceae) or Diplopterys cabrerana shrubs containing a serotonergic 2A receptor agonist, N,N-dimethyltryptamine, a powerful psychoactive substance. Ayahuasca is a traditional psychoactive sacrament that has been used for shamanic ceremonies for centuries. Ayahuasca is acclaimed for spiritual and psychotherapeutic benefits and is gaining popularity in the United States. Potential risks involved with usage of this hallucinogenic drug include psychotic episodes related to N,N-dimethyltryptamine and serotonin syndrome, which can be potentially life threatening. The consequences of ayahuasca use remain uncertain because of poor quality control, unpredictability, and polydrug interactions. Nurses, advanced practice nurses, and other healthcare providers working in outpatient settings, hospitals, and treatment centers need to be familiar with the pharmacology, possible drug interactions, and management for ayahuasca ingestion for optimal decision making. Nurses are well positioned to facilitate understanding and to advise and educate the public about the potential risks associated with ayahuasca ingestion.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Similar articles

References

    1. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Author.
    1. Azarius. (n.d.). Ayahuasca-encyclopedia. Retrieved October 20, 2020, from https://azarius.net/encyclopedia/4/ayahuasca/
    1. Barbosa P. C., Mizumoto S., Bogenschutz M. P., Strassman R. J. (2012). Health status of ayahuasca users. Drug Testing and Analysis, 4(7–8), 601–609. https://doi.org/10.1002/dta.1383 - DOI
    1. Barrett F. S., Schlienz N. J., Lembeck N., Waqas M., Vandrey R. (2018). "Hallucinations" following acute cannabis dosing: A case report and comparison to other hallucinogenic drugs. Cannabis and Cannabinoid Research, 3(1), 85–93. https://doi.org/10.1089/can.2017.0052 - DOI
    1. Bauer I. L. (2018). Ayahuasca: A risk for travelers?Travel Medicine and Infectious Disease, 21, 74–76. https://doi.org/10.1016/j.tmaid.2018.01.002 - DOI

LinkOut - more resources